ASH 2026: Explore Hematology Clinical Research

Thermo Fisher Scientific is proud to be an exhibitor at the ASH Annual Meeting 2026

For more than 30 years, our CRO solutions have enabled drug developers to develop and commercialize their hematology treatments. Success in hematology clinical research requires a provider of CRO solutions with a deep understanding of the disease and a unrelenting dedication to developing the services that patients need.

Our teams bring deep hematology expertise across leukemia, lymphoma, MDS, myelofibrosis, multiple myeloma and rare bleeding disorders – supporting programs from early strategy and feasibility through global clinical trial execution.

Our experienced team can provide the following to your Hematology clinical trials:

Accelerated site startup and increased enrollment using our selected sites
Reduced global site activation timelines through the use of innovative site feasibility and activation strategies
Earlier achievement of enrollment timelines by a unified team approach towards timely interventions to support high enrolling and non-enrolling sites
Timely data analysis by close cross-departmental collaboration

Novel oncology drug development has seen an increasing focus on targeted drugs with innovative mechanisms of action for the treatment of cancer over the last decade.

Our hematology CRO services are here to help you navigate these evolving medical therapies and help move your drug development programs forward. We provide expertise across a wide range of novel therapeutics and therapeutic areas, including cell and gene therapy, ADCs, and radiopharmaceuticals.

In the past five years, we have supported 24 global radiopharmaceuticals studies, which include healthy volunteer studies and range from Phase I to Phase III, as well as 30+ ADC clinical trials globally.

Schedule a meeting or stop by our Booth #1129 to learn more about our commitment to developing novel therapies, our patient & site strategy, and our expert global execution that can help move your hematology clinical trials forward.

Book a meeting

Precision oncology and next-generation sequencing

A precision medicine approach to cancer therapeutics is a biomarker-driven strategy with a laser focus on delivering therapies to the right patients at the right time. This is why predictive biomarker testing has become the basis for selecting appropriate precision therapies for cancer patients. It has helped to transform cancer treatment, which has evolved dramatically over the past 25 years.

We have brought precision medicine capabilities to community sites, empowering them to be an end-to-end solution for our clients. We do so with innovations like Oncomine Solutions, our in-house, high-speed genomic profiling solutions. Oncomine Solutions enable sponsors to solve many of the most common issues faced by precision medicine therapeutics development while allowing for elevated global data into genomic profiling for better study feasibility and site strategy.

Oncomine™ Solutions — the latest technology for fast-profiling and next-generation sequencing of key biomarkers and comprehensive genomic profiling — provides molecular insights to inform the most critical decisions with speed and accuracy.